Kuros Biosciences Ltd. (SIX:KURN) announced the signing of a combination agreement with Xpand Biotechnology B.V. with the intention to acquire Xpand by way of an exchange of all Xpand shares for up to 2.105 million new Kuros shares, subject to customary conditions. Xpand's novel orthobiologic MagnetOs was approved for sale in the European Union in July 2016 and is under regulatory review in the US. VISCHER is advising Kuros; the team is led by Matthias Staehelin with Gian-Andrea Caprez, Angelo Imperiale and Angela Oppliger (all Corporate).